Adherence to Subcutaneous Anti-Tumour Necrosis Factor Treatment in a Cohort of Patients with Rheumatoid Arthritis Before and After the Implementation of a Comprehensive Care Model.
Pedro Santos-MorenoGuillermo Sánchez-VanegasAngelica Monterrosa-BlancoGabriel-Santiago Rodríguez-VargasManuel RiveroPedro A RodríguezOmar-Javier CalixtoAdriana Rojas-VillarragaCarlos Alberto CastroPublished in: Biologics : targets & therapy (2022)
A CCM produced an important increase in the percentage of patients with rheumatoid arthritis adherent to treatment after 24 months of follow-up. It is noteworthy that Golimumab patients were more adherent when compared with other current anti-TNFs treatments.